Cloning and sequencing of VL and VH genes from a novel clone ZCH-7-2F9 of anti-hCD14 monoclonal antibody.
- Author:
Bo-tao NING
1
;
Yong-min TANG
;
Jiang CAO
Author Information
- Publication Type:Journal Article
- MeSH: Amino Acid Sequence; Animals; Antibodies, Monoclonal; genetics; immunology; Base Sequence; Cloning, Molecular; Humans; Immunoglobulin Heavy Chains; genetics; Immunoglobulin Light Chains; genetics; Immunoglobulin Variable Region; genetics; Lipopolysaccharide Receptors; immunology; Mice; Mice, Inbred BALB C; Molecular Sequence Data; Polymerase Chain Reaction; Sequence Analysis, DNA
- From: Journal of Zhejiang University. Medical sciences 2007;36(4):348-354
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo acquire the genes of light chain variable region (VL) and heavy chain variable region (VH) of a novel clone ZCH-7-2F9(2F9) of anti-hCD14 for construction of anti-hCD14 single chain antibody(ScFv).
METHODSFrom the mouse hybridoma cell line 2F9 and its fusion partner murine myeloma cell line NS-1, total RNA was prepared. The VL and VH genes were amplified by RT-PCR with family specific primer pairs, respectively. The PCR products were cloned into pGEM(sound recording copyright sign)-T Easy vectors, then transfected into DH5alpha and the positive recombinants were identified and purified. After sequencing with automatic DNA sequencer the sequences were analyzed online.
RESULTSVL gene of the new clone of CD14 monoclonal antibody (McAb) 2F9 consisted of 321 bps encoding a peptide of 107 amino acid residues, and VH gene of the 2F9 antibody contained 360 bps encoding a peptide of 120 amino acid residues. According to IMMUNOGENETICS online analysis by IMGT/V-QUEST, the VL and VH genes belonged to mouse IGKV and mouse IGHV subgroups, respectively. On the position 23/88 of the light chain and 22/96 of the heavy chain genes there were cysteines, which play the key role in forming disulfo-bond in each chain. Both VL and VH chains had definitely 4 frame regions (FR) and 3 complementary determinant regions (CDR).
CONCLUSIONThe treatment of CML consisting of myeloablative Allo-SCT combined with Gleevec before and after transplantation is an effective and safe method for CML.